Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
Nasdaq Edges Lower; Crude Oil Down 2%
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.
Kinnate Biopharma Receives Fast Track Designation From The U.S. FDA For KIN-2787, An Investigational Pan-RAF Inhibitor
SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug
Kinnate Biopharma Q2 EPS $(0.62) Down From $(0.49) YoY
Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(0.62) per share. This is a 26.53 percent decrease over losses of $(0.49) per share from the same period last year.
HC Wainwright & Co. Initiates Coverage On Kinnate Biopharma with Buy Rating, Announces Price Target of $33
HC Wainwright & Co. analyst Robert Burns initiates coverage on Kinnate Biopharma (NASDAQ:KNTE) with a Buy rating and announces Price Target of $33.
89 Biggest Movers From Friday
Gainers
Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
33 Stocks Moving In Friday’s Mid-Day Session
Gainers
Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.
Kinnate Biopharma To Present Trial Design For Its Pan-FGFR Inhibitor Product Candidate, KIN-3248, At ASCO 2022 June 3-7
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE)
Kinnate Biopharma Q1 EPS $(0.61) Down From $(0.40) YoY
Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(0.61) per share. This is a 52.5 percent decrease over losses of $(0.40) per share from the same period last year.
